Serotonin 5-HT(1B/1D) receptor agonists in migraine: Comparative pharmacology and its therapeutic implications

CNS Drugs

Volumn 10, Issue 4, 1998, Pages 271-286

  Goadsby, Peter J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; ALMOTRIPTAN; ALNIDITAN; AVITRIPTAN; DIHYDROERGOTAMINE; ELETRIPTAN; FROVATRIPTAN; GRANISETRON; METHYSERGIDE; MONOAMINE OXIDASE INHIBITOR; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; NEUROPEPTIDE; ONDANSETRON; PIZOTIFEN; RIZATRIPTAN; SB 20950; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HEADACHE; HUMAN; MIGRAINE; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 0031771420     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810040-00005     Document Type: Review

References (135)

1. Goadsby PJ. A triptan too far. J Neurol Neurosurg Psychiatry 1998; 64: 143-7
2. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 1961; 19: 55-8
3. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965; 88: 997-1010
4. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967; 16: 544-52
5. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960; 10: 107-11
6. Lance JW, Anthony M, Hinterberger H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967; 7: 93-102
7. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203
8. Jasper JR, Kosaka A, To ZP, et al. Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor [h5-HT7(b)]. Br J Pharmacol 1997; 122: 126-32
9. Hartig PR, Hoyer D, Humphrey PPA, et al. Alignment of receptor nomenclature with the human genome: classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 1996; 17: 103-5
10. Phebus LA, Johnson KW, Zgombick JM, et al. Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors - binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997; 61: 2117-26
11. Humphrey PPA, Feniuk W, Marriott AS, et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31: 282-90
12. Bou J, Domenech T, Gras J, et al. Pharmacological profile of almotriptan, a novel antimigraine agent [abstract]. Cephalalgia 1997; 17: 421-2
13. Gupta P, Scatchard J, Shepperson N, et al. In vitro pharmacology of eletriptan (UK-116,044), a potent partial agonist at the '5HT1D-like' receptor in the dog saphenous vein [abstract]. Cephalalgia 1996; 16: 386
14. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17: 145-52
15. Beer M, Middlemiss D, Stanton J, et al. In vitro pharmacological profile of the novel 5HT1D receptor agonist MK-462 [abstract]. Cephalalgia 1995; 15 Suppl. 14: 203
16. Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121: 157-64
17. Brown AM, Parsons AA, Raval P, et al. SB209509 (VML251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors [abstract]. Br J Pharmacol 1996; 119: 110P
18. Martin GR. Serotonin receptor involvement in the pathogenesis and treatment of migraine. In: Goadsby PJ, Silberstein SD, editors. Headache. New York: Butterworth-Heinemann, 1997
19. Fozard JR, Gray JA. 5-HT1C receptor activation: a key step in the initiation of migraine? Trends Pharmacol Sci 1989; 10: 307-9
20. Kalkman HO. Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade? Life Sci 1994; 54: 641-4
21. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1997; 17: 85-92
22. Berde B, Schild HO. Ergot alkaloids and related compounds. In: Born GVR, Eichler O, Farah A, et al., editors. Handbook of experimental pharmacology. Vol. 49. Berlin: Springer-Verlag, 1978
23. Penfield W. Operative treatment of migraine and observations on the mechanism of vascular pain. Trans Am Acad Ophthalmol Otolaryngol 1932; III: 1-16
24. Penfield W, McNaughton FL. Dural headache and the innervation of the dura mater. Arch Neurol Psychiatry 1940; 44: 43-75
25. Goadsby PJ, Silberstein SD, editors. Headache. In: Blue books in practical neurology. New York: Butterworth-Heinemann, 1997
26. Bax WA, Heuven-Nolsen DV, Simoons ML, et al. 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn-Schmiedebergs Arch Pharmakol 1992; 345: 500-8
27. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-42
28. Spira PJ, Mylecharane EJ, Misbach J, et al. Internal and external carotid vascular responses to vasoactive agents in the monkey. Neurology 1978; 28: 162-73
29. Perren MJ, Feniuk W, Humphrey PPA. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetised dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol 1991; 102: 191-7
30. Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilatation - reversal by sumatriptan. Lancet 1991; 338: 13-7
31. Connor HE, Stubbs CM, Feniuk W, et al. Effect of sumatriptan, a selective 5-HT1-like receptor agonist, on pial vessel diameter in anaesthetised cats. J Cereb Blood Flow Metab 1992; 12: 514-9
32. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993; 33: 48-56
33. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60
34. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 1989; 96: 83-90
35. Gupta P, Brown D, Butler P, et al. Preclinical in vivo pharmacology of eletriptan (UK 116,044): a potent and selective partial agonist at the 5HT1D-like receptor [abstract]. Cephalalgia 1996; 16: 386
36. Williamson DJ, Shepheard SL, Hill RG, et al. The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilatation and extravasation. Eur J Pharmacol 1997; 328: 61-4
37. Parsons AA, Parker SG, Raval P, et al. Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist. SB 209509 (VML 251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1996; 30: 136-41
38. Saxena PR. 5-HT in migraine - an introduction. J Neurol 1991; 238 Suppl. 1: S36-7
39. Villalon CM, Bom AH, Boer MOD, et al. Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacol Res 1992; 25: 125-37
40. De Vries P, Apaydin S, Villalon CM, et al. Interactions of GR127935, a 5-HT(1B/D) receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmakol 1997; 355 (4): 423-30
41. Den Boer MO, Villalon CM, Saxena PR. 5-HT1-like receptors mediate changes in porcine carotid hemodynamics: are 5-HT1D receptors involved? Naunyn-Schmiedebergs Arch Pharmacol 1992; 345: 509-15
42. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-11
43. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 1987; 7: 4129-36
44. Dimitriadou V, Buzzi MG, Theoharides TC, et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992; 48: 187-203
45. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251-8
46. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-6
47. Lee WK, Limmroth V, Ayata C, et al. Peripheral GABA-A receptor mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995; 116: 1661-7
48. Limmroth V, Lee WS, Cutrer FM, et al. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 1996; 117: 99-104
49. Yu X-J, Waeber C, Castanon N, et al. 5-carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol 1996; 49: 761-5
50. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993; 626: 303-5
51. Gupta P, Brown D, Butler P, et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist. CP122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116: 2385-90
52. Roon K, Diener HC, Ellis P, et al. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies [abstract]. Cephalalgia 1997; 17: 245
53. Brandli P, Loffler B-M, Breu V, et al. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996; 64: 315-22
54. Lee WS, Moussaoui SM, Moskowitz MA. Blockade by oral or parenteral RPR100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation in guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994; 112: 920-4
55. May A, Gijsman HJ, Wallnoefer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67: 375-8
56. Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17: 785-90
57. Goadsby PJ, Hoskin KL, Knight YE. Substance Pblockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 1998; 86: 337-43
58. Hoskin KL, Goadsby PJ. CP122,288 has no effect on c-fos expression in the trigeminal nucleus caudalis after superior sagittal sinus stimulation [abstract]. Cephalalgia 1997; 17: 402
59. May A, Shepheard S, Wessing A, et al. Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 1998; 121: 1231-7
60. Saxena PR, De Vries P, Wang W, et al. Effects of avitriptan, a new 5-HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmakol 1997; 355 (2): 295-302
61. Yocca FD, Buchanan I, Gylys IA, et al. The preclinical pharmacological profile of the putative antimigraine agent BMS-180048, a structurally novel 5HT1D agonist [abstract]. Cephalalgia 1995; 15 Suppl. 14: 174
62. Couch JR, Saper J, Meloche JP. Treatment of migraine with BMS180048: response at 2 hours. Headache 1996; 36: 523-30
63. Yocca FD, Gylys JA, Smith DW, et al. BMS-181885: a clinically effective migraine abortive with peripherovascular and neuronal 5HT1D antagonist properties [abstract]. Cephalalgia 1997; 17: 404
64. Knight YE, Edvinsson L, Goadsby PJ. Blockade of release of CGRP after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288 [abstract]. Cephalalgia 1997; 17: 248
65. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994; 34: 394-9
66. Adham N, Kao H-T, Schechter LE, et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993; 90: 408-12
67. Branchek T, Archa JE. Recent advances in migraine therapy. In: Robertson DW, editor. Annual reports in medicinal chemistry: central nervous system disease. San Diego: Academic Press, 1997: 1-10
68. Castro ME, Pascual J, Romon T, et al. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 1997; 36: 535-42
69. Pascual J, Arco Cd, Romon T, et al. [3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 1996; 295: 271-4
70. Waeber C, Moskowitz MA. [3H]Sumatriptan labels both 5-HT1D and 5HT-1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmakol 1995; 352: 263-75
71. Goldstein J, Dahlof CGH, Diener H-C, et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 1996; 16: 497-502
72. Limmroth V, Wermelskirchen D, Tegtmeier F, et al. R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of 5HT1D-receptors [abstract]. Neurology 1997; 48: A69
73. Leysen JE, Gommeren W, Heylen L, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Da, human 5-hydroxytryptamine1Db, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996; 50: 1567-80
74. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998; 5: 329-41
75. Goadsby PJ, Sercombe R. Neurogenic regulation of cerebral blood flow: extrinsic neural control. In: Mraovitch S, Sercombe R, editors. Neurophysiological basis of cerebral blood flows control: an introduction. Paris: John Libbey and Company. 1996: 285-322
76. Goadsby PJ, Edvinsson L. Regulation of cerebral blood flow by the parasympathetic nervous system. In: Welch KMA, Caplan L, Reis DJ, et al., editors. Primer of cerebrovascular diseases. San Diego: Academic Press. 1997: 63-6
77. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-6
78. Buzzi MG, Moskowitz MA, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991; 30: 1193-200
79. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69-75
80. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7
81. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-90
82. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994; 117: 427-34
83. Fanciullacci M, Alessandri M, Figini M, et al. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache atlack. Pain 1995; 60: 119-23
84. Diener HC. Substance-P antagonist RPR 100893-201 is not effective in human migraine attacks. In: Olesen J, Tfelt-Hansen P, editors. Proceedings of the VIth International Headache Seminar. New York: Lippincott-Raven, 1996
85. Goadsby PJ, Duckworth JW. Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 1987, 253 (2 Pt 2): R270-4
86. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias. SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain 1997; 120: 193-209
87. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991; 31: 365-71
88. Wolff HG. Headache and other head pain. New York: Oxford University Press, 1963
89. Kaube H, Keay K, Hoskin KL, et al. Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res 1993; 629: 95-102
90. Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 1992; 12: 133-6
91. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119: 1419-28
92. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the non-human primate brain macaca nemestrina: ac-fos immunocytochemical study. J Anat 1997; 190: 367-75
93. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114: 1001-11
94. Goadsby PJ, Knight YE, Hoskin KL. Processing of occipital pain in the caudal trigeminal nucleus: referred pain in primary headache [abstract]. Cephalalgia 1997; 17: 381
95. Goadsby PJ, Gundlach AL. Localisation of [3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29: 91-4
96. Mills A, Martin GR. Autoradiographic mapping of [3H]-sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995; 280: 175-8
97. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17: 153-8
98. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiology study. Brain 1996; 119: 249-56
99. Knight YE, Goadsby PJ. Naratriptan inhibits central trigeminal activity by a 5HT1B/1D receptor [abstract]. Cephalalgia 1997; 17: 403
100. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997; 328: 37-40
101. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996; 67: 355-9
102. Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-92
103. Shepheard SL, Williamson DJ, Williams J, et al. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995; 34: 255-61
104. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587-92
105. Goadsby PJ, Hoskin KL. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5-HT1B/1D receptor: a central action in migraine? Ann Neurol 1998; 43: 711-8
106. Clitherow JW, Scopes DI, Skingle M, et al. Evolution of a novel series of [(N,N-dimethylamino) propyl]- and peperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem 1994; 37: 2253-7
107. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)-1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120: 2171-7
108. Proletti-Cecchini P, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17: 849-54
109. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of the auditory cortical evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic transmission? Neurology 1996; 46: 1404-9
110. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-4
111. Rance D, Clear N, Dallman L, et al. Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor of oral absorption potential [abstract]. Headache 1997; 37: 328
112. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [abstract]. Cephalalgia 1997; 17: 421
113. Milton KA, Allen MJ, Abel S, et al. The safely, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective '5HT1D-like' receptor partial agonist [abstract]. Cephalalgia 1997; 17: 44
114. Kempsford RD, Baille P, Fuseau E. Oral naratriptan tablets (2.5mg-10mg) exhibit dose-proportional pharmacokinetics [abstract]. Cephalalgia 1997; 17: 408
115. Seaber E, On N, Phillips S, et al. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 41 (2): 141-7
116. Morgan P, Rance D, James G, et al. Compartive absorption and elimination of eletriptan in rat, dog and human. Cephalalgia 1997; 17: 414
117. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996; 16 (4): 270-5
118. Fuseau E, Baille P, Kempsford RD. A study to determine the absolute oral bioavailability of naratriptan [abstract]. Cephalalgia 1997; 17: 417
119. Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468-78
120. Goadsby PJ. Is a central site of action of acute antimigraine drugs essential? Cephalalgia 1997; 17 Suppl. 17: 10-1
121. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-81
122. Visser WH, Vriend RHMd, Jaspers NMWH, et al. Sumatriptan in clinical practice. Neurology 1996; 47: 46-51
123. Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients [see comments]. Cephalalgia 1996; 16 (4): 264-9
124. Jackson NC. A comparison of oral eletriptan (UK-116,044)(20-80mg) and oral sumatriptan (100mg) in the acute treatment of migraine. Cephalalgia 1996; 16: 368-9
125. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647-51
126. Visser WH, Lines CR, Reines SA. Dose-finding studies of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1996; 16: 359-60
127. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch Neurol 1996; 53: 1132-7
128. Goadsby PJ. 311C90, a novel 5-HT1B/D agonist: the assessment of efficacy and tolerability in the acute treatment of migraine. Neurology 1997; 48 (3): A86
129. Goadsby PJ. Naratriptan in the treatment of acute migraine attacks. Prescriber 1997; 8: 89-97
130. Gobel H, Boswell D, Winter P, et al. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan [abstract]. Cephalalgia 1997; 17: 426
131. Ryan R, Keywood C. A preliminary study of VML251 (SB209509) a novel 5HT1B/1D agonist for the treatment of acute migraine [abstract]. Cephalalgia 1997; 17: 418
132. Winner P, Ricalde O, Force BL, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-4
133. Massiou H. A comparison of sumatriptan nasal spray and intranasal dihydroergotamine (DHE) in the acute treatment of migraine [abstract]. Funct Neurol 1996; 11 (2/3): 151
134. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361-5
135. Martin GR, Martin RS, Wood J. Long-acting 5-HT1D receptor agonist effects of dihydroergotamine. In: Olesen J, Moskowitz MA, editors. Experimental headache models. Philadelphia: Lippincott-Raven, 1995: 163-7